Archives

Verismo Therapeutics Announces $28 Million Investment from HLB Innovation to Accelerate KIR-CAR Clinical Development

B Investment supports continued Phase 1 clinical advancement of SynKIR™-110 in advanced solid tumors and SynKIR™-310 in B cell non-Hodgkin lymphoma Initial clinical data from… Login to continue reading Login…

Read MoreVerismo Therapeutics Announces $28 Million Investment from HLB Innovation to Accelerate KIR-CAR Clinical Development

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

B SYDNEY, April 15, 2026 /PRNewswire/ — Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today… Login to continue reading Login…

Read MoreKazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

Lonestar Announces StarVault, The World’s First Commercial Space-Based Data Storage Service, and Expansion of its Orbital Data Center with Sidus Space

B Existing Agreement with Sidus Space Amended, Supporting Growing Demand TAMPA, Fla., April 15, 2026 /PRNewswire/ — Lonestar today announced the launch of StarVault, the… Login to continue reading Login…

Read MoreLonestar Announces StarVault, The World’s First Commercial Space-Based Data Storage Service, and Expansion of its Orbital Data Center with Sidus Space

PrecisionLife and Ovation ink collaboration agreement to launch GLP-1 stratification LDT and consumer GLP-1 DNA test in H2 2026

B Companies confirm that markers of weight loss and glycemic control are distinct in preliminary study, with multiple mechanisms identified that provide opportunities to guide… Login to continue reading Login…

Read MorePrecisionLife and Ovation ink collaboration agreement to launch GLP-1 stratification LDT and consumer GLP-1 DNA test in H2 2026